THE USPTO's examiner/examination guidelines may soon change. Ignore all the acronyms associated with that; also ignore the propaganda about it, courtesy of the patent trolls' lobby*. We wrote a couple of rebuttals last week. Will the USPTO change the rules in lieu with a decision or two from CAFC? That partly depends on what CAFC does in the 90-day comment period/window. We're therefore watching these things pretty closely.
In its important Vanda Pharmaceuticals v West-Ward Pharmaceuticals opinion, the Federal Circuit found the claims eligible at step two of the Mayo/Alice test whereas the district court found them eligible at step one
"The headline from Managing IP says that a "patent survives Section 101 test at Federal Circuit" and as we explained many times before the word "survives" implies that the aggressor is the victim."We certainly hope that patent administration and examination staff can see these propaganda sites for what they truly are; they attempt to come across as "professional" "journalism", but they're merely jingoism for a hostile agenda (involves threats, ruinous lawsuits, and forced/imposed bankruptcies).
Speaking of propaganda sites, Patently-O dresses up the propaganda as "scholarly" (clever ploy) and as we'll show later today it's back to PTAB bashing (the so-called 'death squads'). Noting CAFC's take on SCOTUS/Mayo (like the above which is more about Mayo than about Alice), Patently-O advocates patenting by "trick" (the word "trick" is actually in the headline) to bypass the law:
The claims at issue in Vanda were roughly parallel to those found unpatentable in Mayo v. Prometheus. In Mayo, representative claim 1 of the challenged Patent No. 6,355,623 was directed to treatment method that involved (a) administering a drug (6-thioguanine); and then (b) determining blood level of the drug. A low blood level (less than about 230 pmol per 8Ãâ108 red blood cells) indicates a lack of effectiveness and a need for a higher subsequent dose while a high blood level (greater than about 400 pmol per 8Ãâ108 red blood cells) indicates potential for toxicity and that the next dose should be reduced.
In finding the claim invalid, the Supreme Court unanimously held that the correlation between blood level, efficacy and toxicity was an unpatentable law of nature and that the administration and determination steps were already well known in the art and thus insufficient to transform the claim to a patent eligible invention.
In Vanda, representative claim 1 is directed to a method of treating a patient suffering from schitzophrenia by (a) determining whether the patient is genetically a poor metabolizer of the drug (CYP2D6 genotype) then (b) administering iloperidone to the patient (12-24 mg per day if good metabolizer; <12 mg per day if poor metabolizer) in order to reduce the risk of “QTc prolongation” for poor metabolizers.
First the dissent — Chief Judge Prost identified the similarity here and explained her position that “the asserted patent claims [are] directed to a law of nature.” At its crux, the invention began with the discovery of the health problems created by treating folks with lower CYP2D6 activity and recognition that a lower dose would be appropriate.
[...]
I believe that the invention should be patent eligible, the majority’s approach appears to latch onto simple patent drafting tricks as the basis for distinguishing Mayo — an approach directly rejected by the Supreme Court in Mayo.
"They tend to focus only on outcomes that suit them."Michael Risch, another "scholarly" proponent of patent maximalism (he says he's agnostic on software patents, but his past writings suggest otherwise) linked to Patently-O (an article from March) a few days ago. It's about the Federal Circuit statistics, gathered by Jason Rantanen, himself a "scholarly" proponent of patent maximalism. To quote Professor Risch:
Jason Rantanen (Iowa) has already blogged about his new article, but I thought I would mention it briefly has well. He has created a database of data about Federal Circuit opinions.